Phio Pharmaceuticals Says PH-762 Is Well-Tolerated in Phase 1b Skin Cancer Trial
Bitget2026/11/06 14:06- Phio Pharmaceuticals will present final Phase 1b results for PH-762 at SITC’s annual meeting in Phoenix on November 7, 2026.
- Findings suggest PH-762 is well tolerated and could reduce the extent of surgery for cutaneous squamous cell carcinoma.
- A Phase 2b study is planned for the first half of 2027 to further evaluate safety and efficacy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
